PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Dapagliflozin - Chronic Kidney Disease

PAD Profile : Dapagliflozin - Chronic Kidney Disease Important

Keywords :
CKD
Brand Names Include :
Forxiga
Important Information :
If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist team may be prudent prior to dapagliflozin initiation.

Traffic Light Status

Status 1 of 1.

Status :
Green
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
01 June 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends dapagliflozin for treating chronic kidney disease in line with NICE TA 775.

Dapagliflozin will be considered GREEN on the traffic light system.

Key considerations:
If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist team may be prudent prior to dapagliflozin initiation. 

Associated BNF Codes

06. Endocrine System
06.01.02. Antidiabetic drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More